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Summary
Subarachnoid hemorrhage (SAH) is a severe subtype of stroke with poor neurological out-
come in patients despite improved surgical and medical management. It is mostly caused
by aneurysm rupture and leads to dispersion of blood throughout the subarachnoid space.
One main aspect of poor outcome in patients is the formation of vasospasms in big vessels
within the first week after SAH. A part of the artery constricts and therefore decreases blood
flow and brain perfusion. But even patients without these macrovasospasms can present
with severe neurological damage. Consequently, pathologies were investigated within the
early phase, the first 72 hours after subarachnoid hemorrhage, summarized as “early brain
injury” (EBI). EBI is presenting with the formation of vasospasms in small arteries and
arterioles, called microvasospasms, immediately after SAH as previously shown in humans
and experimental animals. The mechanisms behind the formation of microvasospasms are
not completely understood at this point, but they have been linked to acute endothelial ni-
tric oxide depletion. Lack of vascular NO is caused both by NO scavenging by hemoglobin,
as well as by a defect in the endothelial nitric oxide synthase, the main source of vascular
NO in the brain. Nitric oxide is a strong vasodilator in the cerebral microcirculation and
a lack of NO impairs vessel reactivity. Patients with loss-of-function polymorphisms of the
eNOS gene have a higher risk of developing vasospasms after SAH. Further, eNOS has been
shown to produce less NO after SAH, but the consequence of this finding on brain func-
tion and outcome remained unclear so far. Therefore the aim of the current study was to
investigate the importance of eNOS after experimental subarachnoid hemorrhage by using
eNOS deficient mice. The results of the current study demonstrate that eNOS knockout
mice have more severe SAHs as indicated by higher intracranial pressure, lower cerebral
blood flow, larger intracranial blood deposition, and more re-bleedings. These findings are
in line with prolonged tail bleeding times in these animals. On the level of the cerebral
microcirculation in vivo two-photon microscopy revealed a lower vessel density and a de-
creased perfused vessel volume in eNOS deficient mice, which worsened after SAH. These
mice displayed also more microvasospasms than control animals. Finally, these phenotypes
resulted in gene-dose dependent high mortality in homozygous (50%) and heterozygous
(25%) eNOS deficient mice after SAH. These results clearly demonstrate the protective
activity of endothelial NO after SAH and suggests endothelial NO signaling as a potential
novel therapeutic target for SAH.

Kurzfassung
Die Subarachnoidalblutung (SAB) ist eine schwere Form des Schlaganfalls mit schlechter
Prognose. Die häufigste Form stellt die aneurysmatische SAB dar. Dort platzt ein Aneu-
rysma an der Schädelbasis und Blut strömt aus dem Gefäßlumen und verteilt sich im Sub-
arachnoidalraum. Ein Hauptaspekt der schlechten Prognose nach SAB ist die Entwicklung
von Vasospasmen in großen zerebralen Gefäßen in der ersten Woche nach der Blutung. Ein
Abschnitt der betroffenen Arterie verengt sich und limitiert somit die Durchblutung und
als Konsequenz die nutritive Versorgung des Gehirns. Doch selbst Patienten ohne diese
Makrovasospasmen zeigen bereits früh nach SAB schwere neurologische Defizite. Diese
frühe Phase nach SAB, d.h. die ersten 72 Stunden nach der Blutung, wurden unter dem
Begriff
”
Early Brain Injury“ (EBI) zusammengefasst und genauer untersucht. EBI präsen-
tiert sich mit der Ausbildung von Vasospasmen in den Gefäßen der zerebralen Mikrozirku-
lation, wie am Menschen und im Mausmodell gezeigt werden konnte. Die genauen Mech-
anismen hinter der Bildung dieses Mikrovasospasmen (MVS) sind noch nicht vollständig
erforscht, aber sie konnten mit einem akuten Mangel an endothelialem Stickstoffmonoxid
(NO) in Verbindung gebracht werden. Dieser endotheliale NO Mangel ist wohl durch die
Inaktivierung von NO durch Hämoglobin auf der einen Seite und durch einen Defekt der en-
dothelialen NO Synthase (eNOS) bedingt. NO ist ein starker Vasodilatator und ein Verlust
führt zu gestörter Autoregulation der zerebralen Blutgefäße. Patienten mit loss-of-function
Mutationen des eNOS Gens zeigen ein höheres Risiko für Aneurysmen, eine stärkere Ten-
denz zur Ruptur eben dieser und eine verstärkte Entwicklung von MVS nach SAB. Eine
verringerte Funktion der eNOS nach SAB konnte bereits gezeigt werden, allerdings bleibt
unklar inwieweit dies mit dem post-hämorrhagischen Hirnschaden in Zusammenhang steht.
Ziel der aktuellen Studie war daher mit Hilfe von eNOS defizienten Mäuse die Bedeutung
der endothelialen Stickstoffmonoxid Synthase nach experimenteller Subarachnoidalblutung
zu untersuchen. eNOS defiziente Tiere zeigen eine schwerere SAB mit einem stärkeren
Anstieg des intrakraniellen Drucks und einem stärkeren Abfall der zerebralen Durchblu-
tung. Zugleich habe diese Tiere nach SAB größere Hämatome an der Schädelbasis. Des
Weiteren haben eNOS knockout Mäuse eine verlängerte Blutungszeit und eine stark erhöhte
Rate an spontanen Nachblutungen in den ersten 90 Minuten nach SAB. Unter dem Zwei-
Photonen Mikroskop stellt sich eine Störung der Mikrozirkulation, hauptsächlich in ver-
ringerter Gefäßdichte und perfundiertem Gefäßvolumen sowie in erhöhter Anzahl an MVS
dar. Bereits naive knockout Mäuse zeigen diese Defizite der Mikrozirkulation. In der Tat
ähnelt das Bild dem der Wildtyp Tiere nach SAB. Nach SAB zeigen die eNOS defizienten
Tiere eine noch stärkere Verschlechterung der Mikrozirkulation. All dies führte zu einer
stark erhöhten Mortalität bei den Knockout Tieren. Daraus lässt sich schließen, dass en-
dotheliales NO eine starke protektive Wirkung nach SAB entfaltet. Eine Widerherstellung
der NO Signalkaskade könnte somit eine potenziell neues Therapieziel für Patienten mit
SAB darstellen.
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1 Introduction
1.1 Subarachnoid hemorrhage
Depending on its pathophysiology stroke can be divided into two categories. There is
ischemic stroke, where a vessel is occluded by thrombus formation or by an embolus, both
of which subsequently lead to impairment or loss of perfusion. The second subtype is
hemorrhagic stroke. This category includes intraparenchymal/intracerebral bleedings and
subarachnoid hemorrhage (SAH). This thesis focusses on SAH.
1.1.1 Definition
The brain and spinal cord within the skull and the spinal canal are covered by three
connective tissue layers, the meninges: from outward to inward these are the dura mater,
the arachnoid mater, and the pia mater. The subarachnoid space can be found between
the arachnoid and the pia layer. It is filled with cerebrospinal fluid (CSF) and contains
arteries and veins that penetrate the parenchyma so as to provide adequate blood supply
to the brain (see Fig. 1.1).
If bleeding occurs from these vessels into the subarachnoid space - either due to trauma
or spontaneously - it is called subarachnoid hemorrhage (SAH) (see Fig. 1.2).
There are two types of subarachnoid hemorrhage. One is traumatic SAH which occurs
in up to 60% of patients with severe traumatic brain injury[42], the other is spontaneous
SAH which occurs in more than 85% of cases due to spontaneous rupture of aneurysms
located on subarachnoid arteries [7, 60]. The latter type of SAH is the main focus of this
dissertation.
1.1.2 Aneurysms
An aneurysm is a blood vessel deformation which forms due to an acquired or preexisting
structural weakness of the vessel wall. Over time the transmural pressure gradient occurring
during each heart beat may dilate the aneurysm over time thus thinning the vessel wall.
This process may go on until the aneurysm ruptures spontaneously or following an increase
in systemic blood pressure. Aneurysms are categorized according to their morphology as
saccular or fusiform. The most common forms leading to SAH are saccular or “Berry”
aneurysms (see Fig. 1.3a)). The other, non-saccular forms of aneurysms, e.g. fusiform,
dolichoectatic, and dissecting aneurysms, (see Fig. 1.3b [203]) amount to less than 0.1% of
all known cases [6, 170].
2 1. Introduction
Figure 1.1: Anatomy of the subarachnoid space. There are three layers of tissue be-
tween the brain and the skull. From outside to inside the dura mater, the arachnoid mater and
the pia mater. The subarachnoid space is located between the arachnoid mater and the pia
mater. The blood vessels, that supply the brain parenchyma, are located in the subarachnoid
space. https://www.mdguidelines.com/mda/subarachnoid-hemorrhage-non-traumatic
Image reproduced from MDGuidelines with permission from ReedGroup, Ltd. ©2019
ReedGroup, Ltd. All Rights Reserved.
Most aneurysms are located at the skull base in the anterior part of the Circle of Willis
(see Fig. 1.4), most commonly in the anterior communicating artery (35%), the internal
carotid artery (30%), and the middle carotid artery (22%). 30% of patients have multiple
aneurysms [91]. Aneurysm formation can be associated with genetic connective tissue
disorders such as autosomal dominant polycystic kidney disease [159], Marfan syndrome,
or Ehlers-Danlos syndrome, suggesting a genetic risk factor as well.
1.1.3 Incidence and prevalence of aneurysmal subarachnoid
hemorrhage
Incidence and prevalence of aneurysmal subarachnoid hemorrhage The worldwide incidence
of subarachnoid hemorrhage is estimated to be 9/100,000 - except for Finland and Japan,
both of which have a much higher incidence of up to 15-17/100,000 [26]. Over all, the
incidence of SAH remained stable over the past decades [116]. There is a slightly higher
risk for women than men, the peak being around 50-60 years of age [26, 131, 167]. It is
estimated that worldwide approximately 500,000 patients suffer a SAH each year, almost
two-thirds of which are in low- and middle-income countries [78].
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Figure 1.2: Illustration of an aneurysmatic subarachnoid hemorrhage. The saccular
aneurysm located at the medial carotid artery burst and blood flows out of the vessel and
disperses into the subarachnoid space. Courtesy of Mattew Holt, https://www.bodyrender.
com.
1.1.4 Risk factors
There are modifiable risk factors for SAH, such as smoking, alcohol abuse, and arterial
hypertension [43, 86]. Non-modifiable risk factors include sex, age and a family history of
SAH [85, 96].
1.1.5 Clinical manifestations and diagnosis
SAH usually presents with a sudden onset of a very severe headache, also called “thunder-
clap headache”, accompanied by nausea or vomiting [149]. The patient may show signs of
meningeal irritation, sudden loss of consciousness, focal neurologic deficits or seizures [112].
Around 10% to 40% of patients report prodromal events (mostly sudden onset headaches of
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Figure 1.3: Illustration of the two main types of cranial aneurysms.(a) The saccular
form, where the aneurysm has a neck and is formed like a berry. (b) The fusiform aneurysm
which is an elongated dilation that follows the length of the blood vessel.(c) Intraoperative
image showing an aneurysm. a,b: Withers et al. 2013, [203]; c: Courtesy of Dr. Terpolilli.
short duration) caused by minimal SAH, also known as “sentinel leaks”. They may precede
a major hemorrhage by several weeks [146]. As symptoms may be unspecific, minor leak
SAH is often misdiagnosed [40, 196]. Missed sentinel leaks may lead to devastating conse-
quences for the patient, since there is a significant risk of rebleedings. Initial misdiagnosis
happens mainly in patients with minor SAH, but among those it has been associated with
increased mortality and morbidity[101]. SAH is often associated with marked cardiovascu-
lar impairment [138] such as arrhythmias, cardiomyopathy, and autonomic dysfunction [49]
thereby increasing its risk of being overlooked [12]. In a two-center study by Papanikolaou
et al. in 2012, 62% of 37 patients presented with supranormal pulse-wave velocity and 14
patients (38%) presented with left ventricular systolic dysfunction [138]. Another study
recently suspected that up to 10% of cases of sudden out-of-hospital cardio-pulmonary
arrest are in fact caused by SAH [22, 105]. The best way to diagnose SAH is by cranial
computed tomography (CT) scan [195], since on a native scan blood can easily be identified
(see Fig. 1.5).
In order to identify the source of hemorrhage, CT angiography or transarterial angiog-
raphy can be performed (see Fig. 1.6). Once visualized through angiography, the aneurysm
morphology can be reconstructed in 3-D.
In up to 15% of spontaneous SAH cases no distinct bleeding source can be found on
radiological imaging [60, 99, 192]. This may be due to a very small bleeding or due to
delayed diagnosis since only relatively fresh blood can be diagnosed by CT scan [57]. In
this case SAH can only be reliable identified by performing a lumbar puncture or MRI
[191].
1.1.6 Classifications of subarachnoid hemorrhage
Historically, the first grading system for SAH is the Hunt and Hess classification, published
in 1968 [79]. The scale is based on patient symptoms. Unfortunately the categories are
not precisely defined and the scale therefore has low levels of reproducibility and validity
[28]. In 1974 a new scale was introduced in the setting of acute brain injury: the Glasgow
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Figure 1.4: Anatomy circle of Willis and localization of aneurysms. The circle of
Willis is formed by four main arteries. From the base of the scull comes the basilar artery.
It is connected via the posterior cerebral artery to the middle cerebral artery. At that point
it connects with the internal carotid artery. Last, an anterior commuting artery closes the
circle. Saccular aneurysms are mainly located at the circle of Willis. 35% are located on
the anterior communicating artery. Around 30% are found on the internal carotid artery
and around 22% at the middle carotid artery. Only few are located at the posterior cerebral
artery[91].
Coma Scale (GCS) [182]. It is an easy to use grading system of consciousness and coma,
based on three categories: eye opening, motor and verbal response [82] (see Tab. 1.1).
Two other crucial scores for grading subarachnoid hemorrhage include the GCS score:
The World Federation of Neurogical Surgeons scale (WFNS) of 1988 [205] and the Prog-
nosis on Admission of Aneurysmal Subarachnoid hemorrhage scale (PAASH). There are
numerous other grading scales for SAH used worldwide, e.g. like the Oshiro scale, [136].
A comparison of the three major scores is depicted in Tab. 1.2.
The Hunt and Hess scale has the lowest interobserver agreement at 0.48 (95% CI, 0.36 -
0.59) as compared to the World Federation of Neurogical Surgeons scale with an (agreement
of 0.60, 95% CI, 0.48 - 0.73) and the Prognosis on Admission of Aneurysmal Subarachnoid
hemorrhage scale (agreement 0.64. 95% CI, 0.49 - 0.79) [28]. The Fisher scale grades SAH
according to CT findings into four hemorrhage patterns visible in the subarachnoid space
as seen in Tab. 1.3. [50] The common aim of these scales is to allow a quick classification
of patients upon arrival and to predict outcome and risk of complications.
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Feature Response Score
Best eye response
Open spontaneously
Open to verbal command
Open to pain
No eye opening
4
3
2
1
Best verbal response
Orientated
Confused
Inappropriate words
Incomprehensible sounds
No verbal response
5
4
3
2
1
Best motor response
Obeys commands
Localizing Pain
Withdrawal from pain
Abnormal Flexion to pain
Abnormal Extension to pain
No motor response
6
5
4
3
2
1
Total 3-15
Table 1.1: Glasgow coma scale. The glasgow coma scale is divided into three categories:
1) the best eye response, 2) the best verbal response and 3) the best motor response. De-
pending on the response of the patient, a score from 1 to 6 is associated. The three scores
are then added up to form the final score which ranges between 3 (no response in all three
categories) and 15 (best response in all three categories). Modified from: Jain, S., 2018 [82].
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Grade Hunt and Hess Scale WFNS Scale PAASH Scale
I Asymptomatic, minimal headache
and slight nuchal rigidity
GCS score 15 GSC score 15
II Moderate to severe headache,
nuchal rigidity, no neurological
deficit other than cranial nerve
palsy
GCS score 13-14
without focal
deficit
GCS score 11-14
III Drowsiness, confusion, or mild
focal deficit
GCS score 13-14
with focal deficit
GCS score 8-10
IV Stupor, moderae to severe
hemiparesis, possibly early
decerebrate rigidity, and
vegetative disturbances
GCS score 7-12 GCS score 4-7
V Deep coma, decerebrate rigidity,
moribund appearance
GCS score 3-5 GCS score 3
Table 1.2: Comparison of Hunt and Hess, WFNS and PAASH classification of
subarachnoid hemorrhage. All three grade patients from I (best) to V (worst). In the
second row the Hunt and Hess classification takes into consideration symptoms of the patient
and focal deficits. The WFNS Scale, seen in the fourth row depends on the Glasgow Coma
Scale and focal deficits. The last row contains the PAASH scale. This one is only based on
the Glasgow coma scale. Modified from: Degen et al. 2011, Tab. 1 [28].
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Figure 1.5: Cerebral CT scan with subarachnoid blood and angiogramm with
big aneurysm at the circle of Willis.(a,b) On the cerebral CT scan fresh blood is vis-
ible as hyperdense (lighter) compared to the brain parenchyma. It is clearly visible in the
interhemispheric space and the cisterns. (c) On the angiogram, the basilar cerebral artery is
perfused and highlights the circle of Willis. At the bifurcation of the two is displayed a big
saccular aneurysm. Curtesy of Dr. Terpolilli.
1.1.7 Therapy
SAH is a medical emergency and should immediately be treated in a well-equipped neu-
rointensive care unit [127]. As there is tremendous risk of re-bleeding, which will be further
discussed in Section 1.1.9, the primary therapeutic focus is to seal the bleeding site as soon
as technically possible. Patients should be continuously monitored and regularly reassessed
by experienced health care professionals [158]. General management should contain treat-
ment of hyperglycemia [87, 103], hyperthermia [140, 199] and - if necessary - arterial hy-
pertension. The latter must be carefully considered and adapted to the patients individual
needs as a compromise must be found between the risk of re-bleeding facilitated by too high
blood pressure and the risk of infarction with too low blood pressure [115, 202]. If present,
cardiovascular complications need to be addressed appropriately to improve outcome [49].
Aneurysm occlusion can be achieved by open surgery and clipping or by an endovascular
approach. Surgery consists in placing a vessel clip around the aneurysm base, thereby
excluding it from normal blood circulation [20] (see Fig. 1.7). The endovascular approach
consists in placing platinum coils into the aneurysm thereby inducing local blood clotting
and aneurysm occlusion. Alternatively a stenting device may be placed (such as a Flow
diverter stent) in order to prevent influx of blood into the aneurysm [65, 66] (see Fig. 1.8).
Studies disagree on which method leads to better outcome [111, 123, 177]. The decision
should be made individually for each patient, taking into account factors like location of the
aneurysm, accessibility, aneurysm size and the age of the patient. Outcome is comparable
for both procedures [31, 162], but an individual selection of the optimal treatment modality
results in optimal outcome [31].
1.1 Subarachnoid hemorrhage 9
Figure 1.6: Display of saccular aneurysms in different sequences. (a) Digital sub-
traction angiogram displaying a large multiloculated aneurysm arising from the middle cere-
bral artery (b) CT angiogram depicting an aneurysm on the middle cerebral artery. (c) 3-D
reconstruction of an aneurysm ant the bifurcation of the medial carotid artery and the circle
of Willis done based on MRI data. A,b: modified from Fuller G. (2010) [58]; c: Curtesy of
Dr. Terpolilli.
1.1.8 Outcome and impact for society
Although quality of medical intensive care and treatment of SAH have improved over the
last decades, its outcome in general remains devastating. Acute fatality is >50% due to
the initial hemorrhage or complications [163]. Around 15% of patients die during onset of
hemorrhage and before even reaching medical care. Another 30% to 40% die within the first
twenty-four hours after SAH [167, 171]. The 30-day in-hospital mortality for subarachnoid
hemorrhage has been estimated to be approximately 40% (2016). Around 50% of surviving
patients are left with permanent disabilities [36] (see Tab. 1.4).
Hemorrhagic strokes make up only 5% of all strokes [167], but are responsible for 40% of
all stroke related deaths [7]. The mean age of death for patients with ischemic stroke is 81
years, for patients with intracerebral hemorrhage 73 years and for SAH patients 59 years
[84, 131, 167]. Since many SAH patients are in the middle of their professional working
life, the disorder results in a disproportionally high socioeconomic burden [84, 167]. The
cost for the treatment of SAH exceeds five billion Euros per year in the European Union
and the United States alone. Even though ischemic stroke is twenty times more frequent
than SAH, the socioeconomic impact of the two diseases is almost the same [35, 150, 183].
1.1.9 Pathophysiology of subarachnoid hemorrhage
Within seconds after onset of SAH, as blood flows with arterial pressure into the limited
subarachnoid space, intracranial pressure (ICP) raises massively [134]. In animal exper-
iments, the immediate increase of ICP is around 80 mmHg. Many studies proved that
as ICP increases during onset of SAH, the cerebral blood flow (CBF) drops drastically
[11]. As the CBF decreases and at the same time the ICP increases the cerebral perfusion
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Fisher grade CT scan
I No subarachnoid blood visible
II Diffuse or vertical layer <1mm of blood in
subarachnoid space
III Localized clot and/or vertical layer >1 mm
of blood in subarachnoid space
IV Intracerebral or intraventricular hemorrhage
with diffuse or no SAH
Table 1.3: Fischer classification of subarachnoid hemorrhage. The Fisher classifica-
tion is based on blood visible on cranial CT scan. It ranks from Grade I, no visible blood in
subarachnoid space and IV, intracerebral of intraventricular hemorrhage with diffuse or no
SAH. Modified from: Fisher, 1980 [50].
pressure (CPP) is diminished [11, 133]. The CPP is defined as the middle arterial blood
pressure (MAP) minus the intracranial pressure.
CPP = MAP− ICP
If bleeding from the aneurysm continues, ICP rises further and CBF stops. These
patients die on site due to cerebral circulatory arrest. If the bleeding ceases, ICP and
CPP normalize or stabilize. Increased ICP after SAH is associated with the severity of
early brain injury and patient mortality [207, 72]. The transient increase in intracranial
pressure leads to global cerebral ischemia and brain edema. In this scenario the magnitude
of edema correlates very well with the duration of global ischemia and the severity of
the SAH. If brain edema is very pronounced, lethal cerebral herniation may occur [102].
Another complication which may cause herniation is the development of hydrocephalus [33].
After SAH, the presence of blood in the cerebrospinal fluid can impair the absorption of
cerebrospinal fluid (hydrocephalus malresorptivus) or a direct blood clot may obstruct fluid
draining passages (hydrocephalus occlusus) [63, 18]. As space inside the skull is limited,
in both cases the fluid accumulates and leads to an increase in intracranial pressure and
increases the risk of herniation. Once patients survive the initial SAH, the main and most
threatening complication remains re-bleeding [47, 135]. Before 1983 it was believed that
this mostly occurs later than 7 days after the initial hemorrhage [90]. However, today we
know that rebleedings after SAH peak as early as within 6 hours after SAH onset [104, 173].
Hunt and Hess showed a very high incidence of recurrent hemorrhage in their study in 1968:
many patients even bled more than once, and re-bleeding occurred after up to 3 months
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Mortality of SAH %
Total 51
Out-of-hospital death 10 - 15
Mortality first 24 hours 30
day mortality 40
1 - year mortality 40
2 - year mortality 50
Permanent disability 50 - 60
Table 1.4: Mortality of Subarachnoid hemorrhage. The total mortality of subarach-
noid hemorrhage is 51% [163]. Between 10% and 15% are out-of-hospital deaths. 30% of
patients die within the first 24 hours, 40% within the first month[167, 171]. The 1 year
mortality is 40% and the 2 year mortality is 50%. Last, 50% to 60% of patients that survive
subarachnoid bleeding retain permanent disability[36].
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Figure 1.7: Clipping of MCA aneurysm. A 49-year-old woman presented with subarach-
noid hemorrhage. (A) Cerebral angiography demonstrated a 6-mm right MCA bifurcation
aneurysm. Like most MCA aneurysms, this lesion had a wide neck involving the origins of
the insular (M2) MCA divisions. A single clip was applied across the aneurysm neck. (D)
Postoperative angiography confirmed complete clipping (arrows) of the aneurysm. Modified
from Seibert, B., 2011, [170].
after SAH [79]. Their work indicated that within the first two years after SAH almost 90%
of patients (with and without treatment) suffered from at least one episode of re-bleeding.
Almost half of these patients had more than one re-bleeding, 3% four or more events (see
Tab. 1.5). This indicates the importance of recurrent hemorrhage as a complication of
SAH.
Today, after the aneurysm has been treated successfully the risk of re-bleeding decreases
significantly. Very few re-bleedings occur after elimination of the aneurysm. A study in
2018 showed an incidence of 2.3% after coil embolization [95].
1.2 Delayed cerebral ischemia
After the source of bleeding is secured, other aspects determine patient outcome. Five to
seven days after SAH new infarcts may appear on CT scans [68] and focal neurological
deficit may be observed[194]. These delayed changes are attributed to delayed cerebral
ischemia (DCI), a condition associated with worse outcome. The exact mechanisms behind
the formation of delayed cerebral ischemia are not clearly understood. For decades, DCI
was believed to be caused by spasms of large intracranial vessels [25, 51].
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Figure 1.8: Balloon assisted coil embolization. A 74-year-old man with a strong family
history of aneurysmal SAH was found to have a left ophthalmic aneurysm. (A) Lateral view
of a left ICA injection shows a 7.5-mm left ophthalmic artery aneurysm (circled) with a 4.2-
mm neck. The patient underwent balloon assisted coil embolization. (B) Lateral fluoroscopic
view shows the inflated balloon (arrow) with coils being deployed through a microcatheter
within the aneurysm. (C) AP view of the final left ICA injection shows no residual aneurysm.
Modified from Seibert, B., 2011 [170].
1.2.1 Macrovasospasms
Cerebral macrovasospasms have been studied since their first description in 1951 [39].
Ecker and Riemenschneider found, that, in the presence of ruptured cerebral aneurysms,
the caliber of the affected cerebral arteries was drastically reduced. They called this type
of arterial narrowing “arterial spasms” [39]. As arteries constrict, they limit blood flow
and therefore reduce perfusion to the brain parenchyma. Consequently, cerebral ischemia
and poor outcome may occur. In 1978, Weir et al. showed that patients with more
macrovasospasms have a higher mortality than those with less [201]. As indicated in
Section 1.2, it has long been believed that the development of DCI was mainly caused by the
formation of macrovasospasms. Interestingly, it has recently been shown that vasospasms
and DCI do not always occur together. On the one hand, there are patients with vasospasms
who do not show DCI and on the other hand there are those developing DCI without the
detection of vasospasms [193]. In addition to those findings, a large multi-center clinical
study, the CONSCIOUS trial, showed that despite successful treatment of vasospasms,
there was no effect on long-term outcome [117, 190]. Therefore, it was suggested that
delayed cerebral ischemia has to be a multifactorial phenomenon [151]. A clinical study in
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% Nr. of rebleedings
89 ≥1
47 >1
30 2
14 3
3 ≥4
Table 1.5: Number of rebleeings after subarachnoid hemorrhage in patients in
1986. Hunt and Hess counted the number of rebleedings in patients with and without
treatment and for an observation period of 2 years.
Modified from: Hunt and Hess, Ars neurochirurgica, 1968, tab. 9 [79].
2015 found that delayed cerebral ischemia from macrovasospasms does not predict mortality
after subarachnoid hemorrhage [102]. Late patient deterioration could have its origins much
earlier than previously assumed [14].
1.3 Early brain injury
As a consequence of the sobering results from clinical studies addressing large artery spasms
and late brain injury after SAH, more attention was given to the early phase, namely the
first 72 hours after the bleeding. The pathophysiological changes in this time period are
summarized as “early brain injury” (EBI; Fig. 1.9).
1.3.1 Pathophysiological changes
1.3.1.1 Microvascular constriction
Although previous research was more focused on the formation of delayed macrovasospasms
it has since been shown that microvascular constrictions, called microvasospasms (MVS),
occur and play an important role in the pathophysiology after SAH. As early as 1975 a study
on Guinee pigs indicated that the contact of blood with cortical pial micro vessels leads
to vascular contraction [71]. When the diameter of an artery decreases, volume flowrate
decreases by the power of four as stated in the Hagen-Poiseuille Law of fluid kinetics. That
means that vasoconstriction by 16% decreases blood volume flowrate by 50%. On the other
hand, flowrate can be doubled by a dilatation of 19% of the initial diameter (see Fig. 1.10).
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Pathophys-
iological
ICP ↑ CBF ↓ CPP ↓
Impaired Autoregulation
Mechanical
Constriction
Subarachnoid space stretch
Hydrocephalus
Vascular constriction
Endothelium injury, Basal lamina destruction
Permeability ↑
Molecular
NO/NOS pathway alteration
Oxidative stress
Inflammation, Cell death
Platelet activation and aggregation
EBI
Figure 1.9: Summary of early brain injury. Early brain injury consists of three main
mechanism. First, there are the physiological changes like increase in intracranial pressure,
decrease in cerebral blood flow and decrease in cerebral perfusion pressure. On top of these
there is impaired autoregulation. Second, there are mechanical changes during EBI. These
contain constriction and subarachnoid space stretch, as well as development of hydrocephalus
and vascular changes. These vascular changes are constrictions and spasms, endothelial
injury, basal lamina disruption and increased permeability through the blood-brain-barrier.
Third, there are molecular changes. These contain the important alterations in nitric oxide
and nitric oxide synthase pathways, as well as oxidative stress, inflammation, cell death and
platelet activation and aggregation.
Hence, in small arterioles even a small reduction in vessel diameter can have significant
effects on blood flow and parenchymal perfusion, [141].
The acute narrowing of vessels occurs predominantly in arterioles and not in venules
as shown by Friedrich et al. [55]. In their endovascular perforation mouse model of SAH,
more than 70% of arterioles showed constrictions whereas venular calibers were not affected.
Microvasospasms have been demonstrated as early as 5 minutes after SAH in rats [179].
Vessels can either constrict along their whole length or only be affected in some areas. The
latter leads to pearl-string-like microvasospasms, which have been observed in humans
[141, 189] and can be reproduced in mouse models [44, 55, 184] as seen in Fig. 1.11 [189].
Observations in humans suggest an elevated general microvascular tone of vessels in con-
tact with subarachnoid blood [141]. These vessels also show a higher contractile response
[141], as also shown experimentally in rabbits [27]. In addition, animal studies indicate
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Figure 1.10: Hagen-Poisseulles Law of volume flow rate. Hagen-Poiseuilles Law of
fluid kinetics applied to blood vessels states that volume flowrate is proportional to the vessel
radius to the power of four. That means, that on one the one hand, vasoconstriction to 84%
of initial value cuts blood volume flowrate to half of its initial value. On the other hand, the
flowrate can be doubled by a dilatation to 119% of initial diameter.
that the mechanical stress (stretching of the subarachnoid space induced by hemorrhage),
is directly transferred onto unruptured subarachnoid blood vessels and stimulates their con-
striction [8, 89, 167]. Recent studies indicate that the early formation of microvasospasms
after SAH may be one of the major determinants of outcome after SAH and needs there-
fore to be targeted to allow for adequate brain perfusion [55, 183]. In addition to vascular
constriction, arterioles demonstrate a strongly altered reactivity and especially a decreased
response to vasodilation stimuli early after SAH [13].
1.3.1.2 Autoregulation
Under physiological conditions high carbon dioxide (CO2) levels results in dilatation of
cerebral arteries and subsequent increase of cerebral blood flow. In patients, CO2 reactivity
is impaired for up to 7 days after SAH [30]. Studies on mice and primates show that early
after subarachnoid hemorrhage CO2 reactivity is severely reduced [9, 54, 83, 88].
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Figure 1.11: Early microvasospasms in patients and in mice (a) Image of early cere-
bral mircovasospasms in patients. The arrows indicate locations of pearl-string-like spasms.
Uhl et al. Neurosurgery 2003 [189]. (b) microvasospasms in a murine SAH model 3 hours
after SAH. Friedrich et al. 2012 [55].
1.3.1.3 Platelet activation and aggregation
Platelet activation within the first 48 hours after SAH has been observed in clinical settings
[73, 168]. In animal models, activated and aggregated platelets were found within 2 hours
after hemorrhage in big arteries and within 10 minutes after SAH in small intraparenchymal
vessels [23, 56]. This leads to formation of micro emboli, a phenomenon suspected to be, at
least partly, responsible for the so-called “no reflow” phenomenon which was first described
by Adelbert Ames and colleagues in 1968 [5]. They stopped blood flow to the brain in a
rabbit model for more than 5 minutes. They then observed that even when blood flow was
reinitiated reperfusion did not occur in all areas of the brain. This phenomenon has later
also been observed in humans [193], as well as in the SAH animal model [155].
1.3.1.4 Vascular alterations, permeability
Platelets release collagen-IV digestive enzymes when they are activated [56]. This leads to
numerous vascular alterations like endothelial injury and destruction of the basal lamina
[56]. If vessel wall permeability is increased and - thus - the blood-brain-barrier disrupted,
the consequences are oxidative stress and cerebral edema [34].
1.4 Cerebral nitric oxide and nitric oxide synthases
1.4.1 Nitric oxide synthesis
Many of the above-mentioned changes have been linked to Nitric oxide. Nitric oxide
(NO) is a gaseous signaling molecule critically involved in vessel dilatation and neuronal
signaling. NO is synthetized from L-arginine in presence of the co-substrates molecular
oxygen and reduced nicotinamide-adenine-dinucleotide phosphate (NADPH) by the three
differentially localized NO-synthases (Fig. 1.12): The neuronal form, nNOS (NOS I), is
mainly expressed in neuronal cells. It is involved in synaptic plasticity and blood pressure
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regulation [52, 187, 206]. The inducible NO-Synthase, iNOS (NOS II) can be expressed in
many different cell types and is reported to contribute to non-specific immune defense. In
addition, iNOS plays an important role in inflammation and the pathophysiology of septic
shock [52]. The endothelial isoform, eNOS (NOS III) is expressed in endothelial cells and
promotes vessel dilatation. Therefore eNOS is involved in many pathological processes
such as blood pressure regulation, vascular injury [106] and arteriosclerosis [52].
Figure 1.12: Important functions of the different NOS isoforms. (a) Neuronal nitric
oxide synthase is expressed in neuronal cells in the central nervous system (CNS) and in the
peripheral nervous system (PNS). In the CNS, on the one hand, it is involved in synaptic
plasticity, which is important in the learning process and the memory formation. On the
other hand, it takes part in central blood pressure regulation. In the PNS, nNOS produced
NO is an atypical neurotransmitter mediating relaxation of gut peristaltic, penile erection
and vasodilation.
(b) Inducible NOS can be expressed in many different cell types. Its presence was first proven
in macrophages (M). In marcophages it plays an important role in fighting intracellular
bacteria such as Mycobacterium tuberculosis [130, 118] or the parasite Leishmania [176,
200]. In contrast, the iNOS also acts as a mediator of inflammation, and is a major factor
contributing to vasodilation (and therefore drop in blood pressure) in septic shock [148, 204].
(c) Endothelial NOS-derived NO is a strong vasodilator and important in vasoprotection.
eNOS produces NO inhibits platelet aggregation and adhesion to the vessel wall. This also
counteracts smooth muscle cell migration. Modified from Forstermann et al. 2012 [52].
In addition to L-Arginine, NOSs uses flavin adenine dinucleotide (FAD), flavin mononu-
cleotide (FMN) and 5,6,7,8-tetrahydro-L-biopterin (BH4) as co-factors [24]. NOSs are
composed of two monomers, each consisting of one reductase domain and one oxygenase
domain, forming a homodimer (Fig. 1.13). In the reductase domain, electrons are trans-
ferred from NADPH to FAD and FMN. The electrons then get transferred to haem in the
oxygenase domain. In the presence of the above cofactors electrons are used to reduce
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Figure 1.13: Structure and catalytic mechanisms of functional NOS. (a) The NOS
enzymes consist of two monomers, each having an isolated reductase domain that can bind
calmodulin (to enhance electron transfer) [1] and an oxygenase domain. The reductase
domain can transfer electrons from reduced nicotinamide-adenine-dinucleotide phosphate
(NADPH), to flavin-adenine-dinucleotide (FAD) and flavin-mononucleotide (FMN). In the
process molecular oxygen gets reduced to superoxide (O−2 ) [178, 97, 100]. Only in the eNOS
and nNOS elevated Ca2+ concentration is necessary to enhance calmodulin binding.
(b) NOS monomers are unable to bind the cofactor (BH4) or the substrate l-arginine and
cannot catalyze NO production [97, 113]. Only in the presence of haem, NOS can form a
functional dimer [97, 113]. In presence of the substrate l-arginine (l-Arg) and cofactor (6R-
)5,6,7,8-tetrahydrobiopterin (BH4), intact NOS dimers couple their haem. It is important in
the transfer of electrons. From l-Arg and oxygen nitric oxide is formed with l-citrulline (l-Cit)
as the byproduct. In the process ferric haem (Fe3+) receives an electron (*) and can bind
oxygen and form a ferrous-dioxy (Fe2+) species. This one can receive a second electron (**)
from the cofactor. All NOS isoforms contain a zinc ion (Zn) at the dimer interface. Modified
from Forstermann et al. 2012 [52].
oxygen and oxidize L-arginine into nitric oxide and L-citrulline [178]. All three isoenzymes
bind calmodulin which facilitates the transfer of electrons from NADPH to haem. Binding
of calmodulin depends on the intracellular CA2+ level in both eNOS and nNOS, whereas in
the iNOS it is not sensitive to calcium [21, 70]. Since the endothelium is critically involved
in the pathophysiology of SAH and possibly in the formation of microvasospasms, the role
of eNOS may play a prominent role.
1.4.2 Physiological function of endothelial NO-Synthase
Under physiological conditions NO plays an important role in regulating resting perfusion
of the brain. It furthermore is essential for blood pressure regulation [37]. Nitric oxide is
a strong vasodilator in the cerebral microcirculation in response to shear stress, metabolic
demand, and changes of carbon dioxide partial pressure [144]. It influences the diameter of
arterioles and capillaries by targeting smooth muscle cells and pericytes, respectively. In ar-
teries, NO diffuses from the endothelium into smooth muscle cell. There it binds to and ac-
tivates soluble guanylyl cyclase (sGC), which in turn transforms guanosine-monophosphate
(GMP) into cyclic guanosine-monophosphate (cGMP). The second messenger cGMP acti-
vates protein kinases that stimulate the relaxation of smooth muscle cells through calcium
dependent pathways thereby causing vasodilation [64]. In capillaries, NO diffuses from the
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endothelium into pericytes. There it maintains the phenotype of pericytes and inhibits
their transformation into contractile smooth-muscle cells, which may induce microvascular
constriction and release of cytokines [108]. Studies suggest that cGMP also plays a role in
transformation of pericytes to their α-SMA phenotype.
1.4.2.1 Further functions
NO produced by eNOS is a strong inhibitor of platelet aggregation and adhesion to the
blood vessel wall [4]. In addition, it has anti-inflammatory functions, for example by
inhibiting endothelial cell apoptosis and modulating leucocyte adhesion [32]. A study
in 2004 emphasizes the importance of eNOS for neovascularization in mice [3]. NO is
involved in the release of many excitatory neurotransmitters [143, 147]. Its neuroprotective
function [67], as well as an anticonvulsive function [197] have been recognized (Fig. 1.14).
In addition, as previously indicated, nitric oxide is essential for blood brain barrier integrity
[19].
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Figure 1.14: Function of cerebral NO. eNOS produced NO has many important func-
tions in the human brain. First, the vascular autoregulation. NO is a strong vasodilator and
inhibits arterial constriction. Second, nitric oxide inhibits platelet activation and aggrega-
tion, and therefore reducing artheriogenisis. Third, NO has proven to have neuroprotective
function. Fourth, eNOS produced NO plays an important role in inhibition of inflammation
and fifth, it is involved in many neurotransmitter pathways.
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1.4.3 Nitric oxide in subarachnoid hemorrhage
It has been suggested that NO is lacking early after SAH [164, 166, 169]. A triphasic change
with acute decrease after SAH, followed by recovery and increase within 24 hours has been
observed in animal models of SAH [164]. The depletion of nitric oxide is associated with
EBI [177] and delayed macrovasospasms/DCI in humans [38, 92] and in animal model of
SAH [2, 41, 145, 164, 166, 169, 180]. Prevention and complete reversal of macrovasospasms
could be obtained by counteracting NO depletion by intracarotid infusion of nitric oxide
donors in a primate model [145], further indicating the importance of NO in macrovascu-
lar changes after SAH. The exact mechanisms behind the early depletion in nitric oxide
remain unclear. Two possibilities have been further investigated in the last decade: NO
scavenging by hemoglobin and lack/or dysfunction of eNOS. During subarachnoid bleed-
ing hemoglobin comes in contact with endothelial cells. On the one hand hemoglobin may
lead to NO scavenging [69, 154], on the other hand it may inhibit the eNOS and cGMP
pathway [144]. Previous studies indicated that NO depletion early after SAH was mainly
caused by NO scavenging by hemoglobin, vascular neutrophils, or free radicals, as overall
NOS activity remained unchanged in the first 90 minutes after SAH. Lately it has been
clarified that only nNOS and iNOS are not involved in the acute alterations of cerebral NO
levels after SAH [165]. More recent studies confirmed that eNOS expression and activity
are indeed lacking after SAH [108, 139, 144]. It has been shown in SAH patients that
cerebral autoregulation and CO2 reactivity are impaired up to one week after hemorrhage
[30]. As previously mentioned (see Section 1.3.1.2), animal studies indicated that early
after SAH CO2 reactivity is severely decreased [9, 54, 83, 88]. As the autoregulation is
assumed to be mediated mainly by NO produced by eNOS, a lack of the latter would
therefore lead to this impairment. A clinical study in 2004 correlated concentration of
asymmetric dimethylarginine (ADMA), which is an endogenous inhibitor of nitric oxide
synthase, to worse outcome after SAH [107]. This again indicated the importance of eNOS
in the pathophysiology after SAH. Most of the research on eNOS and SAH, however, was
performed using immunohistological methods [139]. Clear in vivo evidence is missing yet.
1.4.4 Patients with endothelial nitric oxide synthase
polymorphisms
Mutations in the eNOS gene are correlated to bad outcome after SAH. Multiple studies
indicated that the presence of the T786C polymorphism of eNOS is associated with an
increased risk for macrovasospasms after SAH [93, 98, 174]. The T786C polymorphism is
a loss-of-function mutation and thus results in a dysfunction in the enzyme and reduced
endothelial NO production.
1.5 Hypothesis and aim of study
Based on the findings described above we hypothesize that lack of NO may represent a
major step in the pathophysiology of SAH. In order to investigate whether this hypothesis
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is valid, we aimed to induce SAH in animals with a complete loss of eNOS function, i.e.
eNOS knock-out mice (Fig. 1.15). This strategy was chosen because specific pharmaco-
logical inhibitors of eNOS are not available. A second motivation for our study was a
publication from 2013 showing that eNOS knockout reduces secondary complications after
subarachnoid hemorrhage [156]. Since these findings, generated in a clinically not par-
ticularly relevant mouse model of SAH, were widely and controversially discussed in the
SAH community, we aimed to investigate eNOS knockout mice using the filament perfo-
ration model of SAH, the currently clinically most relevant SAH model, which does not
only mimic the presence of blood in the subarachnoid space as the model used by Sabri
and colleagues, but in addition also the initial bleeding and the phase of global cerebral
ischemia.
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Figure 1.15: Importance of nitric oxide in subarachnoid hemorrhage. NO depletion
after SAH has been widely shown. It is caused by both NO scavenging by hemoglobin and a
defect in the endothelial nitic oxide synthase. In patients with eNOS polymorphisms, a higher
risk of intracranial aneurysms has been observed. They have an elevated risk of rupture and
after subarachnoid hemorrhage present an increased risk of vasospasms. eNOS knockout
mice have been used to investigate the eNOS NO pathway. But the exact importance of the
enzyme had to be investigated.
2 Materials and Methods
2.1 General
2.1.1 Ethical statement
All experiments were conducted between October 2015 and June 2017 in the Institute
of Stroke and Dementia Research, University of Munich. All procedures performed on
animals, group size calculation, and all statistical methods used to analyze in vivo data
were reviewed and approved by the Government of Upper Bavaria (protocol # Az. 136
- 11). The results of the study are presented in accordance with the ARRIVE guidelines
[94].
2.1.2 Study design
Sample size calculations were performed using SigmaStat (SigmaStat 3.0, Jandel Scientific,
Erkrath, Germany) with the following parameters: alpha error = 0.05, beta error = 0.2,
calculated standard deviation ranged from 15% - 20% (depending on the parameter inves-
tigated), and biologically relevant difference = 30%. Mice were given random numbers by
another researcher and the investigator was therefore blinded to the genotype of the mouse
during both surgery and analysis of the data.
2.1.3 Experimental animals
The eNOS gene, consisting of 52106 base pairs, twenty-eight axons and encoding the eNOS
protein of 1203 amino acids [129], is located on the chromosome 7q36 in humans [120, 128].
Multiple mouse strains for eNOS deficiency have been developed, many with a combined
targeted mutation in another gene, such as the BKSCg-Leprdb NOS3tm1Unc/RhrsJ, a model
suited for studying diabetic nephropathy. The mouse strain currently used, B6.129P2-
NOS3m1Unc/J [80], is a purely eNOS deficient. These mice are suitable for studying hy-
pertension, cardiovascular defects, insulin resistance, hyperlipidemia and lung develop-
ment. They are also used in models for stroke. Other suitable eNOS knockout strains are
Nos3em1(IMPC)Mbp, and Nos3tm282188(L1L2 Bact P ) [48] but they are rarely used due to their
limited availability. eNOS knockout was shown to lead to elevated blood pressure [76] and
to play an important role in remodeling of blood vessels, since eNOS depletion promotes
abnormal vessel remodeling and leads to pathological changes in vessel wall morphology
in mice upon arterial wall injury [152]. eNOS deficient animals show more severe tissue
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damage and worse functional outcome than wild type controls [75, 77, 109]. In models of
global ischemia eNOS depletion worsens outcome as well [137].
eNOS transgenic animals were purchased from Jackson Laboratories (stock # 002684).
In this mouse line, which was developed by Dr. Smithies of the University of North Carolina
[172], a neomycin cassette replaced 129 base pairs of exon twelve of the eNOS gene, which
disrupts the calmodulin binding site of the protein and introduces a premature stop codon
into the transcripts [172]. These transgenic mice have been crossbred back to C57Bl/6 for
over ten generations at the Jackson Laboratories. The purchased homozygous knockout
animals were crossbred in our animal facility with C57Bl/6N from Charles River (Charles
River, Kisslegg, Germany) to obtain heterozygous eNOS deficient mice. For this study,
male and female mice with an average age of 8 weeks and a mean bodyweight of 22.5 g
were used.
Husbandry Mice were housed in maximal groups of five in standard cages (207 x 140
x 265 mm, Macrolon II, Ehret Life Science Solutions, Emmendingen, Germany) under a
12-hour day/12-hour night cycle with free access to water and food. Health screens and
hygiene management checks were performed in accordance with the Federation of European
Laboratory Animal Science Associations guidelines and recommendations [45].
2.2 Experimental subarachnoid hemorrhage
2.2.1 Anesthesia and monitoring
Anesthesia was induced as previously described [185]. Mice were placed in a chamber
flooded with 5% isoflurane (Abbot GmbH & Co. KG; Wiesbaden, Germany) until loss
of consciousness and pain reflexes. They then received an intraperitoneal injection of
0.05 mg/kg bodyweight fentanyl, (Eurovet Animal Health BV, Bladel, Netherlands), 0.5
mg/kg bodyweight medetomidine, (Eurovet Animal Health BV, Bladel, Netherlands), and
5.0 mg/kg bodyweight midazolam (B.Braun Melsungen AG, Melsungen, Germany,). To
maintain anesthesia and analgesia mice received an intraperitoneal injection with half of
the initial dose every hour. Mice were then orotracheally intubated with a tube made from
a 20G venous catheter, placed under the operation microscope (Carl Zeiss AG; Oberkochen,
Germany), and mechanically ventilated (Minivent 845, Hugo Sachs, March-Hungstetten,
Germany) under continuous monitoring of end-tidal CO2 partial pressure by microcapnog-
raphy (Model 340, Hugo Sachs, Germany). The ventilation frequency was adapted to
maintain an end-expiratory pCO2 at 30 mmHg. Eyes and mucous membranes were pro-
tected from exsiccation with eye ointment (Bepanthen Creme, Bayer Vital, Leverkusen,
Germany). Core body temperature was kept at 37 ℃ by a feedback-controlled heating pad
(FHC Bowdoinham, Bowdoin, ME, USA) and a sensor at the hind paw (SpO2-MSE, Kent
Scientific Corporation, Torrington, CT, USA) was used to continuously measure oxygen
saturation and heart rate. Depending on the experiment, mean arterial blood pressure
was either monitored non-invasively before and up to 15 minutes after induction of SAH
by a tail-cuff monitor (Kent Scientific, Torrington, CT, USA) at five-minute intervals, or
2.2 Experimental subarachnoid hemorrhage 25
invasively via a catheter placed in the left femoral artery. For catheter placement, mice
were placed in supine position and the left hind paws were slightly extended and fixed
with tape. The catheter (outer diameter: 0.61 mm, inner diameter: 0.28 mm; Smiths
Medical, Keene, USA) was cut to approximately 30 cm, and its end then thinned over a
lighter and cut angularly. The catheter end is connected to a one ml syringe via a 30G
needle (0.3 x 0.13 mm) and is flushed with heparin (Rathiopharm GmbH, Ulm, Germany)
and then with saline. A 2 cm incision was then made along the thigh of the mouse. The
femoral nerve, artery and vein were dissected with extra care to not injuring the nerve.
A preparatory 5-0 silk suture (Pearsalls Limited 10C103000, England) was placed around
the femoral artery and the distal part of the artery was ligated. A microsurgical vessel
clip (Peter Lazig GmbH, Tuttlingen, Germany) was then placed proximally. The femoral
artery lumen was opened and a saline filled catheter was then inserted into the artery and
fixed with the previously placed silk filament. Then the clip was removed from the vessel
and the catheter connected to the blood pressure measurement system (Perfusor secura;
B.Braun Melsungen AG, Melsungen, Germany). The skin was closed with monofilaments
(Ethibond 5-0, Ethicon, Norderstedt, Germany). Before and during intravital microscopy,
blood pressure was also always monitored invasively. All physiological parameters were
recorded using Lab Chart 8.0 (AD Instruments Pty Ltd, New South Wales, Australia).
2.2.2 Measurement of intracranial pressure and cerebral blood
flow
Intracranial pressure (ICP) was measured continuously by an intraparenchymal probe
(Codman ICP Express, DePuy Synthes, Umkirch, Germany) placed in the contralateral or
ipsilateral epidural space, depending on the subseries as previously described [15, 44]. In-
tracranial pressure was measured starting 15 minutes before until 15 minutes or 90 minutes
after induction of subarachnoid hemorrhage and is given in mmHg. Cerebral blood flow
(CBF) was measured via Laser-Doppler-Flowmetry (Perimed, Järfälla, Sweden) as previ-
ously described [15, 44]; The fiberglass probe was fixed perpendicularly to the skull after
partially removing the temporal muscle in order to measure the ipsilateral or contralateral
territory of the middle cerebral artery. Cerebral blood flow was recorded starting 15 min-
utes before until 15 minutes or 90 minutes after induction of subarachnoid hemorrhage.
Values are given as percent of pre-hemorrhage (=baseline) blood flow (Fig. 2.1).
2.2.3 Tail bleeding time
Bleeding time was determined as previously described [54, 184]. A 1 mm part of the
distal end of the tail was amputated in deep anesthesia. The tail was promptly placed
perpendicularly in temperature 37℃ physiological saline. The arterial bleeding time was
then timed manually.
26 2. Materials and Methods
Figure 2.1: Placement of ICP and CBF probe. Two probes were applied to the mouse
skull. The intracranial pressure probe was inserted through a small hole under the skull and
fixed with cement. The probe measuring the cerebral blood flow was glued to the skull under
the temporal muscle. Both probes were placed on the same side and contralateral to the
subarachnoid bleeding. Modified from Schuller et al. 2013 [161].
2.2.4 The MCA perforation model
Subarachnoid hemorrhage was induced by filament perforation as previously described
[44, 55, 161, 184]. The animal was placed in a supine position after ICP and CBF probe
placement. Depending on the experimental group either femoral artery catheterization or
a tail cuff was used for blood pressure measurements. A 2 cm skin incision was made on the
left side of the neck. Then the common carotid artery as well as the carotid bifurcation were
carefully dissected sparing the vagus nerve. The superior thyroid artery was then ligated
at its origin from the ECA and severed. Two silk sutures were placed around the caudal
part of the ECA to later secure the inserted filament, then the cranial part of the ECA was
ligated. After carefully placing a vessel clip both on the cranial part of the ECA and the
ICA just after the carotid bifurcation a 1 mm short incision was made on the cranial part
of the ECA. A 12 mm long prolene filament (Prolene 5-0, Ethicon, Norderstedt, Germany)
was then inserted into the external carotid artery facing the bifurcation and secured with
the two ligatures. The clips were then removed. The filament was pushed into the ICA and
then advanced intravascularly towards the circle of Willis (Fig. 2.2) until a sharp increase
in intracranial pressure (more than 58 mmHg) and a drop in cerebral perfusion (below 25%
of baseline) indicated vessel perforation.
If these criteria were not met the mice were excluded from analysis. The filament was
quickly retracted and the artery stump ligated. The skin incision was closed with sutures
(Ethibond 5-0, Ethicon, Norderstedt, Germany) and tissue adhesive (3 M Animal Care
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Figure 2.2: Induction of subarachnoid hemorrhage. A filament was inserted through
the external carotid artery (ECA) and pushed forward into the internal carotid artery (ICA)
until it perforates the circle of Willis at the level of the middle cerebral artery (MCA). From
there, the blood disperses into the subarachnoid space. Modified from Schuller et al. 2013
[161].
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Figure 2.3: Physiological parameters before and after subarachnoid hemorrhage.
This image is a display of the different physiological parameters as seen life during surgery.
The top panel depicts the temperature, followed by the pCO2 and the end-tidal pCO2. Un-
derneath the mean arterial blood pressure is displayed. On the graph of the intracranial
pressure the sharp increase during onset of subarachnoid bleeding can be seen. Simultane-
ously the cerebral blood flow drops. On the bottom are located the oxygenation and the
heart rate. The values are shown from 10 minutes before SAH to 15 minutes after SAH.
Products, St. Paul, USA). During SAH induction physiological parameters (temperature,
pCO2, end tidal pCO2, respiratory rate, pulse, blood pressure, oxygen saturation, ICP,
CBF and heart rate) were recorded digitally (Fig. 2.3).
For imaging experiments, mice were monitored for 15 minutes after SAH, then all probes
were removed, and the animals were injected with a 2.5 mg/kg bodyweight Atipamezol
(Laboratorios SYVA, Leon, Spain), 0.5 mg/kg bodyweight Flumazenil (Synthon BV, Ni-
jmegen, Netherlands), and 1.2 mg/kg bodyweight Naloxon (B.Braun Melsungen AG, Mel-
sungen Germany) to antagonize the anesthesia. Animals were then placed in an incubator
at 27.4℃ and 30% air humidity (MediHEATMT, Peco Services Ltd. Brough, Cumbia, UK)
for 2 hours. Mice which did not receive imaging after SAH were monitored for 90 minutes
and then sacrificed.
2.3 Intravital microscopy
2.3.1 Technical background
Fluorescence microscopy was first described by Sir George G. Stokes in 1852. A large
variety of fluorescent molecules, called fluorochromes or fluorophores that emit light of a
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certain wavelength when illuminated, have been discovered since. If a fluorescent molecule
is hit by a photon of the correct wavelength, it is excited, i.e. it absorbs the energy of the
photon and lifts one of its electrons to a higher energy level. Since this higher energy level
is unstable, the electron falls back to its initial energy level thereby emitting a photon of a
longer wavelength. The emitted light disperses spherically in all directions independently
of the direction of excitation [61]. Conventional one-photon fluorescence microscopy is
not optimal for cerebral imaging in vivo. Brain tissue is very sensitive to photo toxicity
and absorbs and scatters too much excitation and emission light [81]. This phenomenon
worsens with increasing depth leading to images of low contrast. In 1990 Denk et al. solved
this problem by building a two-photon microscope based on the “non-linear optical effect
of two-photon excitation” first described by Maria Göppert-Mayer in 1931 [29, 62]. The
idea is that a fluorophore hit almost simultaneously by two photons emits only one photon
with twice the energy, i.e. half the wavelength of the excitation photons. Two-photon-
excitation microscopy has many advantages over one-photon-excitation microscopy. As
only the molecule absorbing two photons at the same time emits light, the image of the
focal point has a high contrast to the surrounding tissue both in horizontal and vertical
dimension (Fig. 2.4) [16].
Figure 2.4: Jab loński-Diagram: Comparison of one- and two-photon-excitation.
On the one hand, in one-photon-excitation-microscopy one photon of short wavelength light
excites a fluorescence molecule. The electrons receive more energy and move to a higher
state. As this state is unstable they soon fall down to the initial level and in the process
produce energy in the form of emitted light and heat. The emission of the focal point is not
very precise, many surrounding molecules get also hit by one photon and emit light. In the
two photon-excitation-microscopy on the other hand the needed energy to excite a fluorescent
molecule is produced by two photons of each half the needed wavelength. Only when both
hit the molecule at approximately the same time this one gets excited. As the surrounding
molecules may be hit by one photon, but not two, the energy is not high enough to excite
them. Hence, the emission of focal point is more precise. Modifed from Burgold, 2013 [16].
This leads to a high intrinsic three-dimensional resolution of the sample. The most
common used laser wavelength is in the range of 650 to 1000 nm. Light of this range can
penetrate deeper into the tissue than light of double the range, which would be needed in
one-photon-excitation-microscopy. Penetration depths of up to 1 µm have been described
for two-photon-excitation-microscopy; in most set-ups, 200 to 700 nm depth can be realis-
tically obtained. In addition, the laser has less energy than lasers of shorter wavelengths
used in one-photon microscopy and leads to less tissue damage. The brain can therefore
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Figure 2.5: Picture of the intact skull over the territory of the middle carotid
artery (MCA) after subarachnoid hemorrhage. Before preparation of the cranial win-
dow, at about 2.5 hours after SAH leaked blood is visible through the skull. The areas
highlighted by arrows are, where blood is visible around the vessels or in the parenchyma.
be imaged for a longer time than in conventional fluorescent microscopy with less photo-
toxic damage [29, 126]. With this setup it is possible to perform precise three-dimensional
imaging of a thin layer of the living brain.
2.3.2 In vivo imaging
For intravital microscopy, mice received a femoral arterial catheter, were placed in prone
position, and were fixed in a mouse head holder (Model 921-E, Kopf Instruments, Tujunga,
USA). The head was slightly rotated to the right, so the temporal bone was plane. A 3 cm
longitudinal incision was made. The skin was elevated by sutures (Ethibond 5-0, Ethicon,
Norderstedt, Germany) to form a skin pocket (see Fig. 2.5). The laser Doppler probe
was placed as described above (see Sect. 2.2.2). The galea aponeurotica was removed,
the skull exposed. A cranial window (1.5 mm x 2 mm; Fig. 2.6) was drilled over the
left middle cerebral artery territory with a precision drill (Rewatronik Products; Wald
Michelbach, Germany) and a diamond drilling head (diameter 0.5, Aesculap GD 8730 R,
B. Braun Melsungen AG, Melsungen, Germany) under continuous cooling with saline in
order to avoid heat damage. The craniotomy was lifted exposing the intact dura which
was immediately covered with saline in order to avoid dehydration.
The mouse was then carefully placed under the microscope (Zeiss LSM 7, Zeiss, Jena,
Germany) equipped with a Li:Ti laser (Chameleon, Coherent, Vision 1, Santa Clara, CA,
USA) and a 20x water immersion objective (Plan Apochromat, NA 1.0, Zeiss, Germany).
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Figure 2.6: Picture of open cranial window (with intact dura) over the MCA
territory. After craniotomy, the areas where blood has been leaking into the parenchyma
are even clearer. Subarachnoid blood can slow be seen surrounding the biggest artery in the
window. The arrows indicate especially obvious points.
Fluoreszeinisothiocyanate (FITC) dextran (0.5% in saline, Merck, Darmstadt, Germany),
a plasma marker, was injected to visualize blood vessels. The size of the cranial window
allowed proper imaging of a maximum of 1200 x 1200 µm (Fig. 2.7 of imaging of the entire
cranial window).
For time reasons four connected, overlapping regions of interest with a size of 425 x
425 µm were imaged. Three-dimensional image stacks (3 µm step distance) were obtained
up to a targeted minimum depth of 400 µm using an imaging software (ZEN 2.3 SP1, Carl
Zeiss Microscopy GmbH, Jena, Germany). These four stacks were later stitched together
to form one big image stack of 800 x 800 µm (Fig. 2.8). Imaging was done every 10 minutes
for a time period of 90 minutes.
2.4 Experimental groups (Tab. 2.1)
To validate the surgical techniques and the model, a standardization series of subarach-
noid hemorrhage with nine mice in a row was performed. To assess the impact of eNOS
deficiency in the acute phase, i.e. up to 90 min after SAH, physiological parameters (tem-
perature, pCO2, ICP, CBF, HR, MAP, Oxygen saturation) were evaluated in homozygous
(eNOS−/−), heterozygous (eNOS−/+), and wild type mice (Fig. 2.9).
Ninety minutes after SAH the mice received an overdose of the drugs used for anes-
thesia (see 2.2.1) and were perfused with paraformaldehyde (PFA). The brain was then
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Figure 2.7: Mapping of the entire cranial window. Maximum size of imaging obtain-
able in this cranial window.
Mouse
strain
Total SAH at
least 15
min
SAH 90
min
Imaging Imaging
after
SAH
WT 40 32 16 8 8
eNOS−/− 38 30 22 8 8
eNOS−/+ 8 8 8 0 0
Table 2.1: Summary of experimental animals numbers. In total 40 WT, 38 eNOS
homozygous knockouts and 8 heterozygous knockouts were used in this study. 32 WT, 30
eNOS−/− and 8 eNOS−/+ mice received SAH and were at least monitored for 15 minutes
afterwards. A total of 16 wildtyps, 30 homozygous and 8 heterozygous knockouts were
observed for a duration of 90 minutes after SAH. Only eNOS−/− and wildtype mice were
imaged via two-photon-excitation microscopy. For both the näıve imaging, as well as the
imaging after SAH 8 mice were operated from each group.
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Figure 2.8: Illustration of cranial window location and two-photon-excitation-
microscopy size. (a) Picture of a mouse brain. The location of the cranial window is shown
over the territory of the left middle cerebral artery (MCA). (b) Picture of the open cranial
window (big square). The four connected regions of interest as shown by the small square. (c)
Superposition of all one hundred slices of the four regions of interest from (b) received by two-
photon-excitation-microscopy. (d) Three-D model of the two-photon-excitation-microscopy
slices from (c).
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Figure 2.9: Experiment I. A total of 16 wildtype (WT) animals, 8 heterozygous
(eNOS−/+) mice and 22 homozygous (eNOS−/−) mice received subarachnoid hemorrhage
after a preparation of around 45 minutes. The physiological parameters were then monitored
for a duration of 90 minutes after which the animals where perfused with paraformaldehyde
and sacrificed.
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Figure 2.10: Experiment II. A total of 8 wildtype (WT) animals, 8 homozygous
(eNOS−/−) received a open cranial window with intact dura and were placed unter the two-
photon-excitation-microscope. They were imaged for a duration of 90 minutes after which
they were sacrificed.
extracted and placed in PFA for preservation. In a second experimental series the cerebral
microcirculation was assessed: First, two-photon-excitation microscopy was performed (for
90 minutes every 10 minutes) in näıve homozygous eNOS knockout and wild type after
cranial window preparation (Fig. 2.10).
Next, the microcirculatory changes in mice after SAH were assessed. Two hours after
SAH induction, mice were re-anesthetized and the cerebral microcirculation imaged by in
vivo microscopy (Fig. 2.11).
2.5 Analysis
Intracranial pressure and cerebral blood flow Data from Lab Chart was extracted using Lab
Chart viewer 8.0, (ADInstruments Pty Ltd, New South Wales, Australia) at a frequency
of 1 Hz, exported to Microsoft Excel and averaged over a period of 20 second.
2.5.1 Re-bleedings
Spontaneous rebleedings after subarachnoid hemorrhage were defined by a sharp increase
of intracranial pressure of more than 10 mmHg within 10 seconds. Such an increase was
automatically detected by using an Excel macro and manually crosschecked.
2.5.2 Determination of bleeding severity
After perfusion and brain extraction a high-resolution image of the skull base was obtained
using a stereomicroscope (Leica M205, Zoom: 10.6 x, resolution: max. 525lp/mm; Meyer
Instruments, Houston, USA). The background was extracted with GIMP (The GIMP
team, GIMP 2.10.6, https://www.gimp.org, 1997-2019)[181]. The amount of blood was
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Figure 2.11: Experiment III. A total of 8 wildtype (WT) animals, 8 homozygous
(eNOS−/−) mice received subarachnoid hemorrhage after a preparation of around 45 minutes.
The physiological parameters were then monitored for a duration of 15 minutes after which
the animals where given drugs antagonizing the anesthesia. They were placed in an incubator
for 2 hours. After that, they were put back under anesthesia and received an open cranial
window with intact dura and placed under the two-photon-exciation-microscope. They were
imaged for 90 minutes and afterwards they were perfused with paraformaldehyde and sacri-
ficed.
determined by counting red pixels. The area is then expressed as percentage of the total
skull base area (Fig. 2.12).
2.5.3 Analysis of two-photon-excitation microscopy
All data was analyzed using ImageJ (Wayne Rasband, National Institutes of Health, USA)
[153, 160]. Microvascular constriction and the number of microvasospasms were evaluated
as previously described [55, 114]. To determine average vessel diameter each vessel was
carefully examined within the different slices of the three-dimensional stack and the widest
diameter in all three plains located and measured. One measurement was taken at least
every 50 µm along the bigger arteries and up to every 15 µm in capillaries. The shortest
diameter within the spasm was then compared to a mean of the two closest non-spastic
areas. The severity of the spasms (s) is given as percent constriction of vessel diameter (a)
compared to non-constricted vessel segments (b,c) (Fig. 2.13).
s =
a
(b+c
2
)
Spasms were rated as present when the vessel diameter of the spastic area was less than
85% of the diameter of non-constricted segments of the same vessel. All measurements
were related to the mean vessel diameter on two baseline images taken 10 min apart.
For the determination of the totally perfused vessel volume all green pixels in each Z-
stack were summed up and those above an intensity-adapted threshold were counted. The
perfused volume was then calculated as the percentage of green pixels in relation to all
pixels.
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Figure 2.12: Blood clot coverage at the base of the brain. Picture of mouse brain
after SAH. The area of dark blood (red colored pixels over a certain threshold) was highlighted
in green. To determine the blood clot coverage at the brain base the number of green pixels
was then divided by the total number of colored pixels of the brain base.
Figure 2.13: Calculation of vasospasm. A spastic area of the arterial blood vessels
was calculated as the following. The diameter at the constricted part was divided by the
mean of two measurements of the surrounding non-constricted areas. Constriction of spasm:
s = a
(b+c
2
)
. A constricted area was considered as spastic with a constriction of less then 85%
of the diameter of the surrounding non-constricted area.
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2.6 Perfusion and brain extraction
At the end of each experiment all mice were deeply anesthetized. Näıve animals were sacri-
ficed by cervical dislocation whereas mice after SAH were perfused with 4% Paraformalde-
hyde (Morphisto GmbH, Frankfurt am Main, Germany). The brain was extracted and
photographed in order to prove SAH.
2.7 Statistical analysis
All calculations were done using a standard statistical software package (SigmaStat 3.0,
Jandel Scientific, Erkrath, Germany). Data is presented as mean ± standard deviation
if not stated otherwise. Comparisons between groups were performed using the Mann-
Whitney Rank Sum Test. Three groups were compared with Kruskall-Wallis ANOVA on
ranks test. In cases in which a statistically significant difference was detected between
groups, Dunnet analysis was performed post-hoc. Statistical difference was assumed at
p<0.05.
3 Results
3.1 Standardization
After surgical training, the MCA perforation model was performed in nine mice to vali-
date the model. SAH resulted in a sharp increase in intracranial pressure to 78.8 ± 21.0
mmHg, followed by a rapid decrease plateauing around 22 ± 6 mmHg after few minutes
(Fig. 3.1). At the same time, cerebral blood flow quickly dropped to around 39.2 ± 23.3%
of baseline values. It recovered within 5 minutes and then very slowly started decreas-
ing again (Fig. 3.2). Mortality in this series was 22% after 24 hours. The results of the
standardization series are comparable to previous series in our laboratory [44].
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Figure 3.1: Standardization Intracranial pressure in wildtype animals. Nine mice
received SAH by perforation at the level of the circle of Willis. The intracranial pressure is
very low before protrusion of the filament. It is not zero as the ICP probe is inserted under
the skull and leads to slightly elevated pressure. At protrusion of the filament (time=0) the
ICP increases rapidly to 78.8 ± 21.0 mmHg. It drops within a few minutes and saturates at a
level of around 22 ± 6 mmHg. The values are shown in mean plus minus standarddeviation.
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Figure 3.2: Cerebral blood flow standardization in wildtype animals. As the
subarachnoid bleeding is induced by protrusion of the filament the cerebral blood flow sharply
decreases to 39.2 ± 23.3% of its initial values. Within a few minutes it recovers to baseline
and from there slowly decreases over time. Values are shown in percent of initial value.
3.2 Results in eNOS deficient mice
3.2.1 Intracranial pressure and cerebral blood flow
After induction of SAH, wild type mice showed a sharp increase in intracranial pressure
to 55.4 ± 11.7 mmHg followed by a recovery to 22 ± 4 mmHg within a few minutes.
Only homozygous animals display a significantly higher increase in ICP (p<0.001 vs. wild
type) to 88.2 ± 25.7 mmHg. In heterozygous mice there was no significant difference to
either of the two other groups as they displayed a mean of 84.7 ± 28.1 mmHg (Fig. 3.3).
In eNOS−/− mice, values then decrease to 30-40 ± 10-20 mmHg, significantly higher as
compared to wild type mice (p<0.008 vs. wild type). Heterozygous mice reached levels of
25.9 ± 7.6 mmHg 10 minutes after SAH.
As shown above, CBF dropped quickly to 42.5 ± 26.9% of pre-hemorrhage baseline
followed by a fast recovery in wild type mice (Fig. 3.4). CBF later dropped continuously
to 88.4 ± 13.7% in wild type mice at 13 minutes after SAH. In eNOS transgenic animals
CBF dropped to lower levels than in wild type mice. (p<0.001 vs.) The effect was more
pronounced in homozygous (20.3 ± 9.0%) than in heterozygous animals (21.8 ± 7.4%). The
drop in CBF in eNOS−/− mice was significantly lower than in wild type mice (p=0.001 vs
WT). No statistical difference was found between heterozygous mice and either of the two
other groups. In homozygous knockout animals the continuous drop after fast recovery in
CBF attained lower levels than in wild type animals. At 13 minutes after SAH it reached
74.4 ± 51.5% in homozygous and 86.2 ± 17.0% in heterozygous animals.
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Figure 3.3: Intracranial pressure after subarachnoid hemorrhage in WT,
eNOS−/+ and eNOS−/−. The intracranial pressure is very low before protrusion of the
filament. It is not zero as the ICP probe is inserted under the skull and leads to slightly
elevated pressure. At protrusion of the filament (time=0) the ICP increases within seconds
to levels of around 55.4 ± 11.7 mmHg for the wildtype mice, and 88.2 ± 25.7 mmHg for the
eNOS deficient mice. In the wildtype group, it drops within few minutes and saturates at a
level of around 22 ± 4 mmHg. The eNOS KO mice need more time to recover the intracranial
pressure and it stays at significantly higher levels compared to the wildtype group (p<0.001
vs WT control). The irregular line of ICP after SAH in the eNOS depleted mice is due to
multiple rebleeding with again increases in ICP in many animals. The ICP 12 minutes after
SAH is still significantely elevated in the eNOS knockout mice compared to the wildtype
controls (p<0.008 vs WT control). The heterozygous animals position themselves between
the homozygous knockouts and the wildtype animals. The values are shown in mean plus
minus standard deviation.
3.2.2 Hematoma area (Fig. 3.5)
In wild type animals, the blood clot covered 3.1 ± 1.8% of the caudal brain surface. In
homozygous eNOS knockout animals, the size of the clot was significantly larger 7.1 ±
2.6% (p=0.001 vs WT control).
3.2.3 Mean arterial blood pressure
Mean arterial blood pressure was within physiological limits in all groups and did not
change significantly over time (Fig. 3.6); there was no difference between groups, but
homozygous knockout animals presented with a slightly higher blood pressure. Directly
after SAH, a small increase was observed in all animals as a reaction to the ICP increase
(Cushing reflex).
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Figure 3.4: Cerebral blood flow after subarachnoid hemorrhage in WT, eNOS−/+
and eNOS−/−. At onset of SAH the cerebral blood flow sharply decreases in all three
groups. In wildtype animals it reaches 42.5 ± 26.9% of initial values, whereas the homozygous
knockout animals reach a significantly lower level of 20.3 ± 9.0% of initial values (p<0.001
vs WT control). The homozygous eNOS deficient animals need more time (around 3 more
minutes) to recover cerebral blood flow. During this time they stay at a significantly lower
level of CBF (p<0.007 va WT control). They do not reach baseline and the CBF decreases
faster than in the wildtype animals. Heterozygous mice show values between those of wildtype
and homozygous mice and show no significant difference to either of the other two groups.
All values are shown in mean plus minus standard deviation.
3.2.4 Re-Bleedings
Wild type animals infrequently experienced re-bleedings after experimental SAH. Re-
bleedings resulted in increases of ICP with concomitant drops in CBF that occurred after
the initial event (Fig. 3.7). In this study, homozygous eNOS deficient mice had a signif-
icantly higher number (3.1 ± 2.4 per animal) of re-bleedings that their WT control mice
(1.1 ±1.3 per animal; p=0.004 vs WT) (Fig. 3.8 & Tab. 3.1). Only half of the wild type
animals, but 62.5% of the heterozygous and 91% of the homozygous eNOS transgenic mice
experienced one or more spontaneous re-bleedings. Thirteen percent of wild type and het-
erozygous animals showed more than two supplementary hemorrhages after SAH; this rate
increased to 23% in homozygous mice. One eighth of the wild type, none of the eNOS−/+
and 18% of the eNOS−/− mice bled three times. Finally, in the wild type animals only
6.25% showed at least four spontaneous rebleedings within the first 90 minutes after SAH,
whereas this number was doubled in the heterozygous (12.5%) and increased up to 32% in
the homozygous eNOS transgenic mice.
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Figure 3.5: Blood clot coverage at the brain base. The area of the brain base that is
covered by the blood clot is compared between wildtype animals and homozygous knockout
animals. Where the wildtype mice show a coverage of a mean of 3.1 ± 1.8% of the brain
base area, the knockouts show a significantly higher coverage of 7.1 ± 2.6% (p<0.001 vs WT
control). The values are shown in mean plus minus standard deviation.
3.2.5 Mortality
Mortality within the first 3 hours after SAH varied significantly between genotypes (Fig. 3.9).
While no wild type animal died within the first 3 hours after SAH, 2 out of 8 (25%) of the
heterozygous and 12 out of 25 (48%) of the homozygous knockout animals did not survive.
3.2.6 Bleeding time
In order to look for a cause of the increased hematoma area and the high mortality in
eNOS transgenic mice, we assessed primary homeostasis by testing the tail bleeding time
(Fig. 3.10). While in control animals bleeding stopped after 1.3 ± 0.2 minutes, bleeding
time in eNOS knockouts was significantly prolonged to 3.4 ± 2.9 minutes (p=0.006 vs WT
control).
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Figure 3.6: Medial arterial blood pressure (MAP) in all three groups. All three
groups were continuously monitored. The eNOS−/− show a slightly higher MAP than die
wildtype mice (85.5 ± 11.5 mmHg compared to 98.9 ± 13.0 mmHg). But as there is a high
standard deviation there is no statistical significant difference between the groups. An onset
of SAH the blood pressure drops in all three groups. It then increases above baseline values
due to the Cushing reflex. The Cushing reflex is a reflex to increase blood pressure when
intracranial pressure increases to maintain cerebral perfusion. The values then reach initial
values where they stay. The values are shown in mean plus minus standard deviation.
3.3 Microcirculatory changes
3.3.1 Microcirculation
After cranial window preparation, SAH-induced changes (perivascular blood) were found
to be more pronounced in eNOS transgenic animals (Fig. 3.11). eNOS deficient mice
displayed a difference in vessel density already before SAH; after the hemorrhage, the
changes (reduced vessel density, constrictions) were even more pronounced (Fig. 3.12. In
homozygous knockouts, the microcirculation appeared less well structured as in healthy
wild type animals. The arteries seemed thinner and vastly interconnected, but showed less
branching. After subarachnoid hemorrhage the perfusion of capillaries in the parenchyma
appeared impaired in wild type mice. The artery looked constricted compared to the näıve
wild type animals. In eNOS deficient animals, the microcirculation was even more severely
impaired; a large number of arteries was constricted and the entire capillary bed was not
perfused.
When quantified (Fig. 3.13), the perfused vascular volume in näıve mice was significantly
smaller (p=0.009 vs WT control) in eNOS homozygous animals at 34 ± 3% of entire imaged
area compared to wild type animals at 38 ± 4% of imaged area. After SAH the difference
became even more pronounced (p=0.001 vs WT control) with a perfused vascular volume
of 35 ± 1% of entire area in WT mice and 30 ± 3% of imaged area in eNOS knockout
animals. In eNOS−/− mice perfused vessel volume was not only smaller than in WT SAH
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Figure 3.7: Exemplary ICP traces for one WT and one eNOS−/− mouse.
animals but also significantly reduced compared to healthy eNOS−/− mice (p=0.02 vs näıve
eNOS−/−). One healthy wild type mouse needed to be excluded from this analysis as it
showed a very big vein within the imaged area not comparable to the other mice. Another
mouse had to be excluded due to technical issues with cranial window preparation.
3.3.2 Microvasospasms
A total of 355 arterial vessel segments with a total length of approximately 62 000 µm were
analyzed (90 vessel segments in healthy wild type animals, 85 in wild type animals after
SAH, 89 in näıve eNOS−/− mice, and 91 in eNOS−/− mice after SAH). In näıve wild type
animals, 0.3 ± 0.2 spasms per vessel segment were detected (Fig. 3.14); 3 hours after SAH,
this number significantly increased to 1.0 ± 0.6 spasms per vessel segment (p=0.006 vs
näıve WT). eNOS−/− animals showed significantly higher numbers of spasms before SAH
(0.9 ± 0.3, p=0.005 vs WT control) and a tendency of increased number of spasms after
SAH (1.4 ± 0.4, n.s.). Of note, the incidence of microvasospasms in näıve eNOS transgenic
mice was almost as high as in wild type animals after SAH. The same pattern was found
for the total number of spasms per animal (Fig. 3.15). Spasms were predominantly located
in smaller vessels with a diameter of 20–30 µm (Fig. 3.16 and 3.17). In wild type mice
subjected to SAH 87.5% of spasms were located in vessels smaller than 30 µm, while in
eNOS deficient mice this rate was 94.7%.
3.4 Summary of results
The present results show that SAH induces a significantly more severe phenotype in eNOS
deficient mice than in wild type controls. SAH is more severe since clot size is larger in
knockout mice and ICP increases and CBF decreases are more pronounced. Furthermore,
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Figure 3.8: Number of rebleedings per animal in the first 90 minutes after sub-
arachnoid hemorrhage.
NOS KO animals experience significantly more re-bleedings. Subsequently, mortality is
significantly higher in eNOS−/− animals. Regarding the cerebral microcirculation, post-
hemorrhagic dysfunction is more pronounced in eNOS transgenic animals, since these ani-
mals had significantly less perfused vessel volume indicating a reduction of microcirculatory
perfusion and a higher number of microvasospasms (Fig. 3.18).
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% of WT
(n=16)
% of eNOS−/+
(n=8)
% of eNOS−/−
(n=8)
Nr. of
rebleedings
50 62.5 91 ≥1
31 25 73 >1
12.5 12.5 23 2
12.5 0 18 3
6.25 12.5 32 ≥4
Table 3.1: Exact number of rebleedings in WT, eNOS−/+and eNOS−/− animals
within the first 90 minutes of subarachnoid hemorrhage. Number of rebleedings in all
three experimental groups shown in % of mice suffering from a certain number of rebleedings.
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Figure 3.9: Mortality within the first 3 hours after subarachnoid hemorrhage
in all three groups. The mortality within the first 3 hours after SAH. Mortality was 0%
in the wildtype mice, 25% in the heterozygous and 48% in the homozygous mice. eNOS−/−
animals show a significantly higher mortality than wild type mice (p=0.001 vs WT control).
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Figure 3.10: Arterial and venous bleeding time in Wildtype and eNOS−/− ani-
mals. Time until bleeding stop was measured in minutes after amputation of the distal 1
mm of the mouse tail. In wildtype animals bleeding stops after 1.3 ± 0.2 minutes. In eNOS
deficient mice the bleeding stopped after a significantly longer time of a mean of 3.4 ± 2.9
minutes (p=0.006 vs WT control). Some mice bled for more then 6 minutes. The values are
shown in mean plus minus standard deviation.
3.4 Summary of results 49
Figure 3.11: Cranial window comparison between wildtype and eNOS−/− mice.
(a) Display of a cranial window in healthy wildtype animals. The window is clear and vessels
are nicely visible. No blood is seen around the arteries. (b) Depiction of a cranial window
in homozygous knockout. They presente with more difficulties during craniotomy. Tiny
bleedings from vessels between dura and skull occur more frequently. (c) Presentation of a
cranial window after SAH in wildtype mice. The blood around the vessels can clearly be seen.
There is more small hemorrhage from dural vessels. (d) Illustration of a cranial window after
SAH in eNOS deficient animals. They are difficult to image. Those few who survive the first
3 hours after subarachnoid bleed, show significant amounts of blood around the vessels and
large amount of hemorrhage in the parenchyma. The small bleedings from severed vessels
during separation of skull and dura occurred the most frequently of all four groups.
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Figure 3.12: Comparison of maximum-intensity stack superposition of four re-
gions of interest in wildtype and eNOS knockout animal without and after SAH.
(a) Display of imaging of 4 regions of interest in healthy wildtype animals. There is one
big artery, dividing into smaller arteries and arterioles. The microcirculation of the capillary
level is highly perfused and interconnected. Vessel diameter ranges from big to very small
and all in between. (b) Depiction of imaging of 4 regions of interest in homozygous knockout.
The microcirculation seems to be not as well structured as in the healthy wildtype animals.
The arteries are thin and there is not the same level of diameter increase at the bifurcations
as in the wildtype mice. Arterioles are vastly interconnected but show less branching and the
capillary level is to as distinct as in the wildtype. There are pearl-string-like spasms along the
vessels. (c) Presentation of imaging of 4 regions of interest after SAH in wildtype mice. The
perfusion of the capillaries in the parenchyma seems impaired. The artery looks constricted
compared to the näıve wildtype and also compared to the big vein, that is coming into the
image from the right lower corner. There are vasospasms visible in the small blood vessels.
(d) Illustration of imaging of 4 regions of interest after SAH in eNOS deficient animals.
Homozygous knockout animals after SAH present a strongly impaired microcirculation. Here
arteries are constricted and have pear-string-like micro vasospasms. The entire capillary level
is not visibly perfused. There is an active bleeding in the top left corner, which casts a shadow
over this area.
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Figure 3.13: Perfused vessel volume in WT and eNOS−/− animals. Display of
perfused vessel volume in the four regions of interest. The number of fluorescent pixels
in the three-D-reconstructed image from the two-photon-excitation-microscopy was counted
and then divided by the total number of pixels in the area. This led to a representation of
the perfused vessel volume in percent of all pixels in the image. In näıve wildtype animals
the perfused volume takes 38 ± 4% of the area. eNOS−/− mice present significantly less
perfused vessel volume of 34 ± 3% (p<0.009 vs WT control). On the right side of the
graph, there is a depiction of perfused vessel volume in both mouse lines after subarachnoid
hemorrhage. Compared to healthy wildtype animals the wildtype animal after SAH show a
reduced percentage of perfused vessel volume of 35 ± 1% (p<0.038 vs näıve control). The
lest perfused vessel volume depicted the eNOS−/− knockouts. They showed a perfused vessel
volume of 30 ± 3% of the entire image. This was significantly reduced compared to both the
wildtype animals after SAH and the näıve eNOS deficient mice (p<009 vs WT control and
p<0.038 vs näıve control).
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Figure 3.14: Numbers of spasms per vessel segment in WT and eNOS−/− animals.
Healthy wildtype animals had a mean of 0.3 ± 0.2 spasms per vessel segment. Compared to in
wildtype animals, in eNOS−/− the number of spasms was significantly elevated (p=0.005 vs
WT control) to a mean of 0.9 ± 0.3 spasms per vessel segment, very comparable to wildtype
animals after SAH, whom present with a mean of 1.0 ± 0.6 spasms per vessel segment. This
number is again significantly increased compared to the näıve control, which present with 0.3
± 0.2 spasms per mouse (p=0.006 vs näıve control). Not surprisingly, eNOS knockout mice
after SAH show the most vasospasms. They obtain a mean of 1.4 spasms per vessel segment.
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Figure 3.15: Numbers of spasms per animal in WT and eNOS−/− animals. Display
of the number of spasms per animal. The number of spasms in eNOS−/− was significantly
elevated compared to wildtype animals (p=0.002 vs WT control) to a mean of 12.5 ± 5.4.
Again, approximately as many as Wildtype animals after SAH, whom display a mean of 12.0
± 11.0 spasms per animal. Compared to the näıve control the number of microvasospasms is
again significantly higher(p=0.04 vs näıve control). eNOS knockout mice after SAH present
the most vasospasms. They obtain a mean of 19.6 ± 8.7 spasms per animal.
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Figure 3.16: Distribution of spasms after subarachnoid hemorrhage in WT and
eNOS−/− mice. In all wildtype animals after SAH I found a total of around 100 spasms, of
which 65 were in vessels smaller than 20 µm and another 19 in the category between 20 µm
and 30 µm of diameter. In the group of eNOS−/− mice after SAH I counted a total of 132
spasms. 125 were located in vessels smaller than 30 µm.
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Figure 3.17: Percental distribution of spasms after subarachnoid hemorrhage in
WT and eNOS−/− mice. Most of the spams were located in the smallest vessels. In the
wildtype animals 78.5% of spasms showed in arterioles smaller than 30% in the wildtype
animals and in the knockouts almost 94.7% presented in this vessel category.
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Figure 3.18: Summary of results. eNOS deficient mice had a stronger subarachnoid
bleeding, indicated by higher intracranial pressure, lower cerebral blood flow, increased bleed-
ing volume and longer bleeding time. They presented more complications, which were an el-
evated number of rebleedings, an impaired microcirculation and an elevated number of micro
vasospasms. Hence, they had a higher mortality.
4 Discussion
4.1 Model
Due to the unpredictable nature of aneurysm ruptures in SAH [188], the analyzable in-
formation retained from patients only begins once they are admitted to the hospital and
monitored. Therefore, the observations are already delayed unless spontaneous re-bleeding
occurs under monitoring. However, recurrent hemorrhage does not accurately represent
the initial bleed, as there are certainly effects of lingering blood from the initial impact. In
order to investigate ultra-early as well as complex pathophysiological changes, e.g. after
subarachnoid hemorrhage, animal models are indispensable. Thanks to genetically modi-
fied animals in vivo experiments allow detailed insights into causal relationships between
molecular pathways and functional as well as histopathological outcome. In order to de-
liver clinically relevant information an animal model for subarachnoid hemorrhage needs to
fulfill the following criteria: It needs to be as close to the human presentation as possible.
Hence, it must simulate the rupture of a cerebral aneurysm and show both the bleeding
magnitude and dispersion of blood observed in patients. The mortality of the model must
be comparable to humans so as to allow correct interpretation of its variations. Lastly,
it needs to be highly standardized. The first model of SAH was published by Barry et
al. in 1979 [10]. In their model, they perforated the basilar artery in rats through a
midline craniotomy. To induce artery rupture, the tip of a microelectrode was advanced
through the dura mater and arachnoid mater into the basilar artery lumen. Since then
more than 60 models in 7 different species have been developed to investigate subarachnoid
hemorrhage. Only a few are reliable and consistent [119]. The two most commonly used
models of SAH are the circle-of-Willis-perforation model [161] and the cisternal injection
model [17, 110]. In the cisternal injection model, autologous blood (and saline as a control)
is injected directly into the cistern, without any vessel injury. The easiest injection site
is the cisterna magna; however, most SAHs in patients occur in the anterior circulation;
therefore, the model was adapted to an injection in the perichiamsatic area [157, 186].
Animals exposed to the injection model are suitable to study delayed vasospasms but not
for the investigation of early brain injury and delayed ischemia [125] since the model has
some major disadvantages: 1. there is no endothelial injury to simulate the rupture of an
aneurysm, 2. the injection needle perforates the brain parenchyma, so the differentiation
between cerebral damage caused by the needle and the damage caused by the injected
blood is difficult, and 3. the cisternal injection model has a very low bleeding-induced
mortality of only 0-15%, which does not fully represent clinical SAH. Further, some injec-
tion models use already hemolysed blood, a procedure not fully representing actual SAH
[142]. For the current study the middle cerebral artery perforation model was used. As in
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this model SAH is initiated by perforation of a blood vessel, it simulates the rupture of a
cerebral aneurysm well. The site of perforation corresponds to the location of aneurysmal
SAH in humans. The acute changes in physiological parameters like intracranial pressure
and cerebral blood flow correspond to those observed in patients. In addition, this model
has a mortality of 30% to 50%. Thus, among all available SAH animal models the middle
cerebral artery perforation model resembles the clinical situation most adequately. A com-
monly discussed limitation of the perforation model is that the amount of bleeding and
hemorrhage severity cannot be controlled, leading to a relatively large standard deviation
of outcome parameters. At the same time, the contribution of the initial global ischemia
cannot be differentiated from the effect of blood in the subarachnoid space since controls
addressing the effect of ICP are not possible. A minor disadvantage of this model is that
it is technically quite challenging. This problem can be overcome by intensive surgical
training; however, this process is time consuming and not every researcher may reach the
same skill level. Since the aim of this study was to investigate early changes in both mi-
crocirculation and physiological parameters after SAH in the most significant SAH model,
the circle-of-Willis-perforation model seems to be the best suited one.
4.1.1 Anesthesia
To be certain that the observed changes after experimental SAH solely derive from hem-
orrhage, it is necessary to ascertain that the used anesthesia confounds the experiment as
little as possible. Most importantly, the used anesthesia should not affect systemic blood
pressure and cerebral blood flow. Regarding isoflurane, an anesthetic agent commonly
used as in animal models of SAH, one must consider that it causes peripheral vasodilation
and subsequent hypotension and impairs cerebral autoregulation [74, 198]. Anesthesia
with chloral hydrate affects both, the cardiovascular and pulmonary system, leading to
decreased blood pressure [46]. Thus, in this study anesthesia was induced with a triple
combination of fentanyl, medetomidine and midazolam. This combination has been re-
ported to have a very small impact on autoregulation and systemic blood pressure [185].
Therefore, it seems best suited for the current study.
4.1.2 Intravital microscopy
The murine model is well-suited for intravital microscopy of the cerebral microcirculation
because mice - in contrast to rats - have a transparent dura mater. Even when a two-
photon-excitation-microscope is used the maximal imaging depth in rat brain is only 70 µm,
while in mice 500 µm can easily be achieved [132]. Therefore, a murine SAH model in
combination with a cranial window and intact dura mater was chosen for the current
study.
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4.2 Experimental animals
The most commonly used experimental animals are rodents. There are many reasons for
their preference. They are easy to breed and simple to care for. There is also the possibility
of creating genetically modified mice. Many findings on subarachnoid hemorrhage and its
immediate effects have been done in mice and therefore choosing a mouse model facilitates
comparison between new and old data. A disadvantage of a murine model is that, as mice
are very small, the surgery becomes more technically challenging and needs assistance
like the use of operative microscopes. In contrary to humans, the rodent brain is not
gyrencephalic. This has to be considered in interpreting and translating findings from
mouse to human. In different hemorrhage models the distribution of blood after SAH
varies. In the mouse model, blood distributes mainly along blood vessels while in humans
the blood distributes predominantly along the brain sulci. This may not be a major
disadvantage, since blood vessels suppling the brain are located within sulci. Hence, the
cerebral vascular pathologies after SAH may be to some extent comparable in mice and
humans [161]. Pharmacological inhibitors of eNOS are available, e.g. L-NG-Nitroarginine
(L-NNA) or Asymmetric dimethylarginine (ADMA), however, their specificity is under
debate [108]. As this study was designed as a proof of concept, a complete inactivity of
the eNOS enzyme was targeted in order to obtain no eNOS produced NO. In transgenic
mice, a complete lack of the enzyme can be obtained by deletion or disruption of the gene.
There are available NOSIII deficient mice, which are easy to obtain and breed, e.g. the
B6.129P2-NOS3m1Unc/J mouse line used in the current study. Results cannot be translated
directly from knockout animals to humans, but they are a valuable tool to investigate the
importance of pathophysiological molecular pathways. One must consider though, that
the eNOS enzyme is already absent during the development of the eNOS knockout mice.
Therefore, it is only partly reliable as a mimic of acute enzyme defects. In eNOS depleted
animals, compensatory mechanisms may be present. Hence, ultimate proof may only be
provided by inducible eNOS knockout mice, which are, however, not available yet.
4.3 Importance of eNOS after SAH
The current study reveals a significant difference between eNOS knockout and non-trans-
genic/wild type control animals. The transgenic mice have more severe subarachnoid
bleeding indicating a vital role of eNOS in the pathophysiology of SAH. In the mice with
functional eNOS, the increase in ICP is less severe than in those with heterozygous or
homozygous eNOS knockout. As high intracranial pressure is associated with large bleeding
volumes our results in eNOS knockout mice indicate that loss of endothelial NO leads to
more severe hemorrhage. In accordance with this hypothesis eNOS knockout had larger
clots at the skull base after SAH. Hence, eNOS may be important for stopping arterial
bleeding. This assumption is supported by the prolonged tail bleeding time in eNOS
deficient mice observed in the current study. Published data on bleeding times in eNOS
knockout mice are not equivocal. In a study by Freedmann et al. in 1999 eNOS knockout
mice demonstrated a reduced venous bleeding time [53]. In this study blood clotting
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was determined after a single puncture in the dorsal tail vein with a 23-gauge needle.
Another study in 2003 reported eNOS knockout animals to have a longer tail bleeding
times [121]. Since the venous puncture method is not comparable to the Ivy bleeding time
used by Matsushita and by us, our results are well in line with the current literature. The
underlying mechanisms for this phenotype is hard to explain since NO dilates vessels and
has well-known anti-adhesive effects [124]. Hence, lack of NO should cause vasoconstriction
and increased platelet adhesion and is therefore expected to shorten rather than prolong
arterial bleeding. The only possible explanation may be that eNOS depletion promotes
abnormal vessel remodeling and leads to pathological changes in the morphology of vessel
walls, thus resulting in prolonged bleeding [152]. An alternative explanation for longer
tail bleeding times and more severe SAH in eNOS deficient mice could be the previously
observed hypertension observed in these mice, a finding corroborated in the current study.
Hypertension is a main risk for SAH in humans and can cause more severe bleeding. eNOS
deficient mice of older age have been shown to be indeed hypertensive [76], however, this
was shown in different knockout mouse strains than the one used in the current study [122]
[175]. In the current study, the eNOS depleted mice had a slightly increased medial arterial
blood pressure. But as there was no statistical difference between groups, this may be an
insufficient sole explanation for stronger subarachnoid hemorrhage in these animals.
4.3.1 Microcirculation
As previously indicated, nitric oxide is a strong vasodilator in the cerebral microcircula-
tion in response to shear stress, metabolic demand, and changes of carbon dioxide partial
pressure [144]. Lack of NO after SAH is caused both by NO scavenging by hemoglobin
[165], as well as by a defect in the endothelial nitric oxide synthase, the main source of
vascular NO in the brain [108, 139, 144]. eNOS produced NO inhibits vasoconstriction and
promotes vasodilation. This could be confirmed in the present study by showing impaired
microcirculatory blood flow by two-photon microscopy. eNOS−/− mice have less parenchy-
mal capillaries and the perfused vessel volume is significantly decreased as compared to
wild type animals. This could be seen both in arterioles as well as in capillaries further in-
dicating the importance of eNOS in arterial constriction mediated by the cGMP pathway,
and in capillaries mediated by pericyte modification [64] [108]. The observed number of
microvasospasms early after SAH indicate an importance of eNOS in the inhibition of such
arterial narrowing. The number of spams in näıve eNOS mutant mice corresponded to that
of wild type mice after SAH and further increases after SAH. As indicated earlier, eNOS
might play an important role in neovascularization [3]. This could explain the observed
microcirculatory defect in vessel density and structure as eNOS is already lacking when
the microcirculation is formed. As a consequence, it is difficult to differentiate between
microcirculatory impairment due to SAH or eNOS knockout. A way around this dilemma
is to compare the microcirculation of näıve eNOS transgenic mice with the same mouse
line after SAH. The observed impairment (reduced perfused vessel volume, increased num-
ber of microvasospasms) increased significantly after SAH. Therefore, we conclude that
both mechanisms play a role for the observed phenotype: the microcirculation of eNOS
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knockout mice is already impaired before SAH, but worsens thereafter due to lack of NO.
Considering the phenotypes described so far in eNOS deficient mice after SAH, it is not
surprising that these mice have an increased mortality after hemorrhage. These findings
are well in line with the worse outcome of SAH patients with loss-of-function mutations in
the eNOS gene. Quantitatively it is important to consider, that while 50% of the homozy-
gous transgenic eNOS mice died within three hours after SAH, mortality in heterozygous
knockout mice was only 25%. This indicates, that even a small amount on functional eNOS
has protective effects after SAH.
4.4 Conclusion and outlook
Genetic elimination of eNOS leads to worse outcome after SAH. eNOS knockout mice show
stronger bleedings with higher intracranial pressure and larger clots at the base of the skull.
This could indicate an important role of eNOS in counteracting vessel injury and bleeding.
At the same time the autoregulation is more severely impaired in the knockout animals
than in the wild type control group. Cerebral blood flow decreases more and compensatory
mechanisms are insufficient to counteract this reaction. CBF remains reduced for a longer
period of time than in the control group and drops faster after the initial recovery. This con-
firms the importance of eNOS for the regulation of basal cerebral blood flow and systemic
blood pressure. eNOS knockout mice show more re-bleedings and prolonged tail bleeding
times further supporting the role of eNOS for hemostasis after vessel injury. Regarding
the cerebral microcirculation, eNOS deficiency causes a reduced capillary density and a
more severe rarefication of cerebral capillaries after SAH. Hence, we conclude that eNOS
and endothelial NO play an important protective role after SAH. Therefore, restoring or
enhancing endothelial NO production and/or function acutely after SAH may represent a
promising future therapeutic strategy. Inhaled NO, as suggested by our laboratory [184],
or directly targeting downstream NO signaling may be viable options.

Appendices
Abbreviations
CBF Cerebral Blood Flow
CCA Common Carotid Artery
CO2 Carbon Dioxide
DCI Delayed Cerebral Ischemia
EBI Early Brain Injury
ECA External Carotid Artery
eNOS endothelial Nitric Oxide Synthase
GSC Glasgow Coma Scale
ICA Internal Carotid Artery
ICP Intra-Cranial Pressure
MCA Medial Carotid Artery
MVS Micro-Vaso-Spams
NO Nitric Oxide
SAH Subarachnoid Hemorrhage
WT Wildtype
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